Amendments to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound represented by Formula I:



I

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

Ar is phenyl;

m = 1, 2, 3, or 4;

n = ~~0~~, 1, 2, 3, or 4;

X is a bond, O, NH or $S(O)_k$, wherein k is 0, 1 or 2;

A is selected from the group consisting of: $-CO_2H$, $-PO_3H_2$, $-PO_2H_2$, $-SO_3H$, $-SO_2CH_3$ $-PO(R^8)OH$,





each R^1 is independently selected from the group consisting of: hydrogen, ~~halo,~~ hydroxy, ~~$-CO_2H$,~~ and C_{1-4}alkyl, ~~C_{1-4}alkoxy, C_{1-4}alkylthio and aryl,~~ wherein said C_{1-4}alkyl~~, C_{1-4}alkoxy and C_{1-4}alkylthio are each~~ is optionally substituted from one up to the maximum number of substitutable positions with halo ~~and wherein said aryl is optionally substituted with 1-5 substituents independently selected from halo and C_{1-4}alkyl~~, or

when m is 2, 3, or 4, two R^1 groups on adjacent carbon atoms may be joined together to form a double bond;

each R^3 is independently selected from the group consisting of: hydrogen, ~~halo,~~ hydroxy, ~~$-CO_2H$,~~ and C_{1-4}alkyl, ~~C_{1-4}alkoxy, C_{1-4}alkylthio and aryl,~~ wherein said C_{1-4}alkyl~~, C_{1-4}alkoxy and C_{1-4}alkylthio are each~~ is optionally substituted from one up to the maximum number of substitutable positions with halo ~~and wherein said aryl is optionally substituted with 1-5 substituents independently selected from halo and C_{1-4}alkyl~~, or

when n is 2, 3, or 4, two R^3 groups on adjacent carbon atoms may be joined together to form a double bond;

R^2 and R^4 are each independently selected from the group consisting of: hydrogen, ~~halo,~~ hydroxy, ~~$-CO_2H$,~~ and C_{1-4}alkyl, ~~C_{1-4}alkoxy, C_{1-4}alkylthio and aryl,~~ wherein said C_{1-4}alkyl, ~~C_{1-4}alkoxy and C_{1-4}alkylthio are each~~ is optionally substituted from one up to the maximum number of substitutable positions with halo ~~and wherein said aryl is optionally substituted with 1-5 substituents independently selected from halo and C_{1-4}alkyl~~;

or R^1 and R^2 or R^3 and R^4 residing on the same carbon atom may optionally be joined together to form a carbonyl group,

each R^5 is independently selected from the group consisting of: halo, aryl, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{1-6}alkylthio and C_{3-6}cycloalkoxy, said C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{1-6}alkylthio and C_{3-6}cycloalkoxy optionally substituted from one up to the maximum number of substitutable positions with halo,

R^8 is selected from the group consisting of: C_{1-4}alkyl and aryl, wherein said C_{1-4}alkyl is optionally substituted with 1-3 halo groups and aryl is optionally substituted with 1-5 substituents independently selected from the group consisting of: halo, C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{1-4}alkylthio and C_{3-6}cycloalkoxy, said C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{1-6}alkoxy, C_{1-4}alkylthio and C_{3-6}cycloalkoxy optionally substituted from one up to the maximum number of substitutable positions with halo,

C is phenyl or **C** is not present;

when **C** is not present then **B** is selected from the group consisting of: C_{5-16}alkyl, C_{5-16}alkenyl, C_{5-16}alkynyl, ~~-CHOH-C_{4-15}alkyl, -CHOH-C_{4-15}alkenyl, -CHOH-C_{4-15}alkynyl,~~ and C_{4-15}alkoxy, ~~-O-C_{4-15}alkenyl, -O-C_{4-15}alkynyl, C_{4-15}alkylthio, -S-C_{4-15}alkenyl, -S-C_{4-15}alkynyl, -CH_2-C_{3-14}alkoxy, -CH_2-O-C_{3-14}alkenyl, -CH_2-O-C_{3-14}alkynyl, -(C=O)-C_{4-15}alkyl, -(C=O)-C_{4-15}alkenyl, -(C=O)-C_{4-15}alkynyl, -(C=O)-O-C_{3-14}alkyl, -(C=O)-O-C_{3-14}alkenyl, -(C=O)-O-C_{3-14}alkynyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkenyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkynyl, -N(R^6)(R^7)-(C=O)-C_{3-14}alkyl, -N(R^6)(R^7)-(C=O)-C_{3-14}alkenyl and -N(R^6)(R^7)-(C=O)-C_{3-14}alkynyl~~, and

when **C** is phenyl then **B** is ~~selected from the group consisting of:~~ C_{1-6}alkyl~~, C_{1-5}alkoxy, -(C=O)-C_{1-5}alkyl, -(C=O)-O-C_{1-4}alkyl and -(C=O)-N(R^6)(R^7)-C_{1-4}alkyl; and~~

~~R^6 and R^7 are independently selected from the group consisting of: hydrogen, C_{1-9}alkyl and -$(CH_2)_q$-phenyl, wherein q is 1 to 5 and phenyl is optionally substituted with 1-5 substituents independently selected from the group consisting of: C_{1-3}alkyl and C_{1-3}alkoxy, each optionally substituted with 1-3 halo groups~~.

2. (original) The compound according to Claim 1 wherein:

Ar is phenyl and

the group **–B-C** is attached to the phenyl ring at the 3- or 4-position.

3. (original) The compound according to Claim 1 wherein X is a bond, m is 2 and n is 2.

4. (original) The compound according to Claim 1 wherein X is selected from O, NH or S, m is 1 and n is 2.

5. (canceled)

6. (currently amended) The compound according to Claim 1 wherein **C** is not present and **B** is selected from the group consisting of: C_{5-16}alkyl, C_{5-16}alkenyl, C_{5-16}alkynyl, ~~-CHOH-C_{4-15}alkyl, -CHOH-C_{4-15}alkenyl, -CHOH-C_{4-15}alkynyl,~~ and C_{4-15}alkoxy~~, -O-C_{4-15}alkenyl, -O-C_{4-15}alkynyl, C_{4-15}alkylthio, -S-C_{4-15}alkenyl, -S-C_{4-15}alkynyl, -CH_2-C_{3-14}alkoxy, -CH_2-O-C_{3-14}alkenyl, -CH_2-O-C_{3-14}alkynyl, -(C=O)-C_{4-15}alkyl, -(C=O)-C_{4-15}alkenyl, -(C=O)-C_{4-15}alkynyl, -(C=O)-O-C_{3-14}alkyl, -(C=O)-O-C_{3-14}alkenyl, -(C=O)-O-C_{3-14}alkynyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkenyl, -(C=O)-N(R^6)(R^7)-C_{3-14}alkynyl, -N(R^6)(R^7)-(C=O)-C_{3-14}alkyl, -N(R^6)(R^7)-(C=O)-C_{3-14}alkenyl and -N(R^6)(R^7)-(C=O)-C_{3-14}alkynyl~~.

7. (currently amended) The compound according to Claim 1 wherein **C** is phenyl and **B** is ~~selected from the group consisting of:~~ C_{1-6}alkyl~~, -C_{1-5}alkoxy, -(C=O)-C_{1-5}alkyl, -(C=O)-O-C_{1-4}alkyl and -(C=O)-N(R^6)(R^7)-C_{1-4}alkyl~~.

8. (currently amended) The compound according to Claim 1 wherein:

B-C is selected from the group consisting of:

(1) **B** is C_{7-10}alkyl and **C** is not present,

(2) **B** is C_{6-9}alkoxy and **C** is not present, or

(3) **B** is C_{1-6}alkyl ~~or C_{1-5}alkoxy~~ and **C** is phenyl.

9. (previously presented) The compound in accordance with Claim 1 wherein:

when X is a bond then m is 2 and n is 2,

when X is O, NH or S then m is 1 and n is 2, and

the group –**B-C** is attached to the phenyl ring at the 3- or 4-position.

10. (currently amended) The compound in accordance with Claim 9 wherein **C** is not present and **B** is selected from the group consisting of: C_{5-16}alkyl, C_{5-16}alkenyl, C_{5-16}alkynyl, ~~-CHOH-C_{4-15}alkyl, -CHOH-C_{4-15}alkenyl, -CHOH-C_{4-15}alkynyl,~~ and C_{4-15}alkoxy~~, -O-C_{4-15}alkenyl, -O-C_{4-15}alkynyl, C_{4-15}alkylthio, -S-C_{4-15}alkenyl, -S-C_{4-15}alkynyl, -CH_2-C_{3-14}alkoxy, -CH_2-O-C_{3-14}alkenyl, -CH_2-O-C_{3-14}alkynyl, (C=O)-C_{4-15}alkyl, (C=O)-C_{4-15}alkenyl, (C=O)-C_{4-15}alkynyl, (C=O)-O-C_{3-14}alkyl, (C=O)-O-C_{3-14}alkenyl, (C=O)-O-C_{3-14}alkynyl, (C=O)-N(R^6)(R^7)-C_{3-14}alkyl, (C=O)-N(R^6)(R^7)-C_{3-14}alkenyl, (C=O)-N(R^6)(R^7)-C_{3-14}alkynyl, N(R^6)(R^7)-(C=O)-C_{3-14}alkyl, -N(R^6)(R^7)-(C=O)-C_{3-14}alkenyl and -N(R^6)(R^7)-(C=O)-C_{3-14}alkynyl~~.

11. (original) The compound in accordance with Claim 10 wherein **C** is not present and **B** is C_{7-10}alkyl.

12. (original) The compound in accordance with Claim 10 wherein **C** is not present and **B** is C_{6-9}alkoxy.

13. (original) The compound in accordance with Claim 9 wherein **C** is phenyl and **B** is C_{3-6}alkyl.

14. (original) The compound in accordance with Claim 9 wherein **A** is selected from the group consisting of: –CO_2H, -PO_3H_2, -PO_2H_2, -SO_3H and -PO(R^8)OH.

15. (currently amended) A compound selected from the group consisting of:






NH2
OH
O
P
OH
OH
NH2
OH
O
P
OH
OH
N
S
N
NH2
N
N
S
N
NH2
N
N
S
N
NH2
N
N
S
O
O
N
NH2
N
N
S
O
O
NH2
O
P
OH
OH
NH2
OH



or a pharmaceutically acceptable salt of any of the above.

16. (original) A method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a

compound in accordance with Claim 1 in an amount that is effective for treating said immunoregulatory abnormality.

17. (original) The method according to Claim 16 wherein the immunoregulatory abnormality is an autoimmune or chronic inflammatory disease selected from the group consisting of: systemic lupus erythematosis, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves ophthalmopathy and asthma.

18 to 27. (canceled)

28. (original) A method of suppressing the immune system in a mammalian patient in need of immunosuppression comprising administering to said patient an immunosuppressing effective amount of a compound of Claim 1.

29. (original) A pharmaceutical composition comprised of a compound in accordance with Claim 1 in combination with a pharmaceutically acceptable carrier.